Evidence map›Paper›PMID 40738896›Full record

ArticleNPJ breast cancer2025

Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer.

Silvia Steinbauer, Jamie D Cowles, Mohammad Ali Sabbaghi, Marle Poppelaars, Azaz Hussain, Marina Wagesreither, Daniela Laimer-Gruber, Jozsef Tovari, Gergely Szakacs, Agnes Csiszar

Abstract read
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Silvia Steinbauer *Center for Cancer Research, Medical University of Vienna, Vienna, Austria.
Jamie D Cowles *Center for Cancer Research, Medical University of Vienna, Vienna, Austria.
Mohammad Ali SabbaghiCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.
Marle PoppelaarsCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.
Azaz HussainCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.
Marina WagesreitherCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.
Daniela Laimer-GruberDepartment of Biomedical Imaging and Image-Guided Therapy, Division of Structural and Molecular Preclinical Imaging, Medical University of Vienna, Vienna, Austria.
Jozsef TovariDepartment of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.
Gergely SzakacsCenter for Cancer Research, Medical University of Vienna, Vienna, Austria. gergely.szakacs@meduniwien.ac.at.
Agnes CsiszarCenter for Cancer Research, Medical University of Vienna, Vienna, Austria. agnes.csiszar@meduniwien.ac.at.

Funding

Austrian Science Fund DOC 59-833City of Vienna Fund Innovative Interdisciplinary Cancer ReasearchH2020-ICT-2020-2 101016964National Research, Development and Innovation Office TKP2021-EGA-44National Research, Development and Innovation Office,Hungary K-147410Österreichischen Akademie der Wissenschaften DOC-Stipendium
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is associated with poor prognosis and high recurrence, driven by residual tumor cells that survive chemotherapy. To monitor therapy response in vivo, we established a clinically relevant TAC regimen (docetaxel, doxorubicin, cyclophosphamide) in mice bearing mammary tumors derived from K14cre;Brca1

Identifiers

PMID40738896
PMCPMC12311029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.